This Week at FDA: Biden administration turns to “march-in” rights to combat high drug prices

This Week at FDA

This Week at FDAJoanne S. Eglovitch

Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceMedical DevicesPharmaceuticalsProduct developmentQuality Assurance and ControlUnited States